Testosterone and Erythrocyte Lifespan
The Journal of Clinical Endocrinology & Metabolism · 2024
DOI: 10.1210/clinem/dgae434 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Melissa C McMartin und 8 weiteren Autor:innen. Beteiligte Einrichtung: ANZAC Research Institute, University of Sydney, Concord Repatriation General Hospital, Concord Hospital, Sydney, NSW 2139, Australia. Hauptthemen laut MEDLINE: Testosterone, Erythrocytes, Receptors, Androgen, Mice, Knockout. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 58 Literaturangaben.
Abstract (Originalsprache)
Context
Endogenous and exogenous androgens increase circulating erythrocytes and hemoglobin but their effects on erythrocyte lifespan is not known.
Objective
To investigate androgen effects on immature and mature erythrocyte lifespan in humans and mice using novel nonradioactive minimally invasive methods.
Design
Human erythrocyte lifespan was estimated using alveolar carbon monoxide concentration and blood hemoglobin in Levitt's formula in hypogonadal or transgender men before and up to 18 weeks after commencing testosterone (T) treatment. Erythrocyte lifespan was estimated in androgen receptor knockout and wild-type mice after T or DHT treatment of intact females or orchidectomized males using in vivo biotin labelling of erythrocyte surface epitopes for reticulocytes (Ter119+CD71+) and 2 markers of erythrocytes (CD45–, Ter119+CD71–) monitoring their blood disappearance rate by flow cytometry.
Results
Before treatment, hypogonadal and transgender men had marked reduction in erythrocyte lifespan compared with controls. T treatment increased erythrocyte lifespan at 6 weeks but returned to pretreatment levels at 18 weeks, whereas serum T and blood hemoglobin were increased by T treatment remaining elevated at 18 weeks. In mice, T and DHT treatment had higher erythrocyte (but not reticulocyte) lifespan but neither orchidectomy nor androgen receptor inactivation significantly influenced erythrocyte or reticulocyte lifespan.
Conclusion
We conclude that hypogonadal men have reduced erythrocyte lifespan and acute androgen-induced increase in circulating erythrocyte lifespan may contribute to the well-known erythropoietic effects of androgens, but longer term effects require further investigation to determine how much they contribute to androgen-induced increases in circulating hemoglobin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ANZAC Research Institute, University of Sydney, Concord Repatriation General Hospital, Concord Hospital, Sydney, NSW 2139, Australia.
- Andrology, Concord Repatriation General Hospital Concord Hospital, Sydney, NSW 2139, Australia.
- Respiratory Medicine Department, Concord Repatriation General Hospital Concord Hospital, Sydney, NSW 2139, Australia.
ORCID-Profile: David J Handelsman
Zitieren
APA
McMartin, M. C., Savkovic, S., Romano, A., Lim, S., Muir, C. A., Jayadev, V., Conway, A. J., Seccombe, L., & Handelsman, D. J. (2024). Testosterone and Erythrocyte Lifespan. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae434
Vancouver
McMartin MC, Savkovic S, Romano A, Lim S, Muir CA, Jayadev V, et al. Testosterone and Erythrocyte Lifespan. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgae434
BibTeX
@article{McMartin2024,
author = {McMartin, Melissa C and Savkovic, Sasha and Romano, Adelina and Lim, Sarina and Muir, Christopher A and Jayadev, Veena and Conway, Ann J and Seccombe, Leigh and Handelsman, David J},
title = {Testosterone and Erythrocyte Lifespan},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
doi = {10.1210/clinem/dgae434}
}
EUVIMED